Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: levomilnacipran Clear all
Completed Phase 4 Interventional Results available

Effect of Milnacipran on Pain in Fibromyalgia

NCT01288807
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipram
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Not applicable Interventional Results available

Novel Medication as a Potential Smoking Cessation Aid

NCT02265367
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Levomilnacipran, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia

NCT01173055
View directory record Official record
Conditions
Fibromyalgia
Interventions
milnacipran, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism

NCT01337700
View directory record Official record
Conditions
Autism Spectrum Disorder, Asperger Syndrome, Aspergers Syndrome
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

NCT01207453
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
24 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2014 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

Trial of Levomilnacipran in Geriatric Depression

NCT02466958
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
levomilnacipran, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 2 Interventional Results available

Effect of Milnacipran in Chronic Neuropathic Low Back Pain

NCT01225068
View directory record Official record
Conditions
Low Back Pain
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

NCT01014585
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Not listed
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2011 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 3 Interventional

Study of Milnacipran for the Treatment of Fibromyalgia

NCT00098124
View directory record Official record
Conditions
Fibromyalgia
Interventions
milnacipran hydrochloride
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
80
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2007 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Not applicable Interventional Results available

Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine

NCT01393522
View directory record Official record
Conditions
Chronic Migraine
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Timothy Smith
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
St Louis, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 25, 2026, 1:35 PM EDT
Withdrawn Phase 3 Interventional

Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran

NCT01221740
View directory record Official record
Conditions
Back Pain
Interventions
Savella
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

NCT00969150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
25
States / cities
Scottsdale, Arizona • Encino, California • Los Alamitos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

NCT03569475
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Fluoxetine, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
7 Years to 17 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
51
States / cities
Little Rock, Arkansas • Beverly Hills, California • Corona, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 4 Interventional

"MILNACIPRAN" in Subjects With Chronic Shoulder Pain

NCT01289236
View directory record Official record
Conditions
Chronic Shoulder Pain
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Valera Bussell
Industry
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Sep 25, 2026, 1:35 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia

NCT01328002
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
13 Years to 17 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Fresno, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Sep 25, 2026, 1:35 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia

NCT00793520
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 30, 2010 · Synced Sep 25, 2026, 1:35 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population

NCT01418651
View directory record Official record
Conditions
Fibromyalgia
Interventions
Savella
Drug
Lead sponsor
Banner Health
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

NCT00969709
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
38
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

NCT01085812
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
30
States / cities
Beverly Hills, California • Encino, California • Garden Grove, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

NCT01077375
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Sacramento, California • Cromwell, Connecticut • Danbury, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Sep 25, 2026, 1:35 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The Savella Pregnancy Registry

NCT01026077
View directory record Official record
Conditions
Fibromyalgia
Interventions
Not listed
Lead sponsor
Syneos Health
Other
Eligibility
18 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 25, 2026, 1:35 PM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 25, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

NCT01034462
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Dothan, Alabama • Highlands Ranch, Colorado • Boca Raton, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Sep 25, 2026, 1:35 PM EDT